Enterprise Value

0.00

Cash

31.51M

Avg Qtr Burn

N/A

Short % of Float

5.48%

Insider Ownership

9.73%

Institutional Own.

29.87%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Klisyri (Tirbanibulin ointment) Details
Skin disease/disorder, Actinic keratosis

Approved

Quarterly sales

Oral docetaxel + encequidar Details
Solid tumor/s, Cancer, Prostate cancer

Failed

Discontinued

Oral paclitaxel + encequidar Details
Metastatic breast cancer, Cancer, Solid tumor/s

Failed

Discontinued

Failed

Discontinued

KUR-501 Details
Neuroblastoma

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Oral Paclitaxel + KEYTRUDA (Pembrolizumab) Details
Non-small cell lung carcinoma, Cancer, Solid tumor/s

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

KUR-502 Details
B-cell malignancies

Failed

Discontinued